ProMIS Neurosciences Overview, updated July 29, 2020 Toronto Stock Exchange (TSX) ticker: PMN OTCQB ticker: ARFXF
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
ProMIS Neurosciences Overview, updated July 29, 2020
Toronto Stock Exchange (TSX) ticker: PMN OTCQB ticker: ARFXF
1
Forward looking statement: safe harbor
This slide deck may contain certain forward-looking information. Such information involves known and unknown
risks, uncertainties and other factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All forward-looking statements are based on the
Company’s current beliefs as well as assumptions made by and information currently available to it as well as
other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date of this slide deck. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings available online at www.sedar.com. Actual events may
differ materially from current expectations. The Company disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information, future events or otherwise.
2
ProMIS Neurosciences overview
• Unique technology platform, rapid, cost-effective value creation
• COVID serology test – current test among industry best, goal to create a 2nd iteration that can
confirm immunity using ProMIS proprietary reagents
§ Expected need for MMs – 100’s of MM’s of accurate immunity tests
• Alzheimer’s and dementia mission and portfolio: Treat – Detect – Prevent
§ PMN310 potential best in class therapy, scientific superiority to likely first in class Biogen’s aducanumab
§ Mid-2021 expected approval for aducanumab
• Entered rapidly growing AD/dementia screening and diagnosis market – JV with leading diagnostic lab
• Initial proof of concept for Alzheimer’s vaccine – ramping up vaccine development
• Numerous near-term catalysts
• Highly experienced management team and Boards
3
Unique proprietary platform offers multiple opportunities for value
creation: timelines contingent on availability of adequate capital
Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021
COVID-19 Scientific evaluations
Serology/Immunity and assay COVID-19 Serology/Immunity Assay potential revenue – multiple sources
Assay development
PMN310 PMN310 Phase 1 clinical trial in AD
Best in class AD PMN310 IND enabling work (CMC – manufacturing; GLP Toxicology) patients – biomarker and clinical
antibody therapy endpoints
Neurodegenerative Equipment purchase Neurodegenerative disease: potential detection assay revenue, potential
Disease and assay validation diagnostic revenue
Diagnostics/Assays
Alzheimer’s Vaccine Develop vaccine using ProMIS proprietary peptide antigens, preclinical validation, initiate IND enabling work
Therapy Development Diagnostic Development Diagnostic Revenue 4
ProMIS unique technology platform: the key to unlocking value
Antibody
Y
Toxic Protein Conformational
or virus Epitope
Antibodies bind to targets called EPITOPES ( )
which have a specific conformation or shape
5
ProMIS unique technology platform: the key to unlocking value
Antibody ProMIS has unique capability to predict epitopes including
Y their shape and make precise replicas – peptide antigens
Predict epitope
Design and
including shape:
create an exact
Supercomputer
replica
Computations
Peptide Antigen
Toxic Protein Conformational Highly Specific - Antibody Therapies
or virus Epitope Peptide antigens - Diagnostics
Make “best in class” - Vaccines
Antibodies bind to targets called EPITOPES ( )
which have a specific conformation or shape
6
ProMIS portfolio of therapies and diagnostics is based on the unique platform
Alzheimer’s Disease COVID Serology
PMN310 Epitopes for Serology Assay
“Best in class” Y neutralizing detecting neutralizing
Alzheimer’s Tx antibodies antibodies:
Immunity
RBD1 of
spike
Coronavirus
Toxic Oligomers Conformational
of amyloid Epitope
1RBD = Receptor binding domain of spike protein 7
COVID-19 pandemic: need for serology assays that can
confirm protective immunity
• Situation
• Currently limited, evolving understanding of human immune response to COVID-19 exposure
• Historically rapid vaccine development; vaccines will be approved with very little information about
variability and durability of immune response
• Numerous existing serology assays provide accurate information about exposure to COVID-19,
including Roche, Siemens, ProMIS/BCNI
• But exposure does not necessarily mean immunity, the ability to resist re-infection
• ProMIS approach to evaluation of protective immunity
• ProMIS peptide antigens (n=18) identified on RBD of COVID-19 virus
• Peptide antigens may represent targets for neutralizing antibodies
• Test sera from patients exposed to COVID-19 for neutralizing activity in laboratory assays with live
coronavirus or pseudo-coronavirus
• Goal: A high throughput, cost effective assay that accurately correlates with gold standard
tests of antibody-based immunity
8
There is a way to measure antibody immunity…but much too expensive and
cumbersome…ProMIS/BCNI are working to create a high volume, cost-effective assay
PROMIS ASSAY
COVID-19 Immunity is complex
Do antibodies in the blood
sample bind COVID-19 antigen? • Cellular (T-cells) vs humoral (antibodies)
YES • High variability
Y Y Y Y Patient has
been exposed • Quality of immunity after COVID infection
Y
YY Y • Quality of immunity after vaccination
• Duration of immunity (months, years?)
Blood Y Y Y Y YES • Immunity in elderly, other subgroups
sample Patient is • Infection may not lead to immunity from re-
immune infection
Do neutralizing antibodies bind v ProMIS assay to provide answers
ProMIS peptide epitopes?
9
If results of neutralization assay based on ProMIS proprietary antigens
are positive in Q4 2020, ProMIS may seek revenue in several ways
• Offer ProMIS unique peptide antigens in multiple non-exclusive licenses to multiple global
diagnostics players (Roche, Siemens, etc) ; $2-$6 per test potential
• Deals with vaccine manufacturers for serology testing in clinical trials and post-marketing
• Collaborate with a SPR instrument company (Danaher, Bruker), to seek EUA (Emergency
Use Authorization) approval for our assay on a high throughput SPR platform
• Serology testing for large projects e.g. province of Ontario, BC
• Potential revenue opportunity Q4/2020, 2021
10COVID serology testing opportunity
Roche Abbott Siemens Ortho
- Major global players in current COVID serology, all sell test kits to diagnostics labs
- Common to validate reagents on SPR (our platform), then sell reagents on a cost/test basis to them
- Goal: create an assay that provides information about antibody immunity useful enough so that
none of the four want to be left out
Abbott CEO Robert Ford in FORBES, July 17
“As vaccines become available, we would anticipate continued surveillance testing to monitor and assess for both natural and
vaccine related immune response, which would be followed by a steady state of ongoing monitoring and tracking of vaccine
protection…..that’s where I think we will see an increase in serology and antibody testing. I see that that’s going to be an
opportunity for us and other companies that have the antibody test, I see that as being a real demand driver on the serology side”
11Alzheimer’s disease profoundly impacts patients, caregivers and society
“Will Bankrupt Medicare
if Therapy is not developed”
Direct and Indirect Costs
Today in the US $500BB….
…. and the number
is tripling by 2030….
Despite two active decades of clinical trials, there are not yet any approved
disease modifying therapies → a pressing, unmet medical need
12ProMIS Neurosciences: an integrated strategy
to address Alzheimer’s disease
Using ProMIS proprietary epitope prediction platform
AD characterized by brain accumulation
of misfolded proteins: Detect Treat Prevent
• Extracellular Amyloid Beta (Aβ), then
• Intracellular Tau (Neurofibrillary Tangles) ProMIS/BCNI Joint PMN310 Amyloid Vaccine
Toxic oligomeric species lead to: Venture Provide best in class Devise safe, effective
Create state-of-the- anti-amyloid anti-amyloid and/or
• Synaptic dysfunction and loss
art diagnostic therapeutic anti-tau vaccines to
• Degeneration and death of neurons
clinical platform for antibody that binds induce a specific
• Neuroinflammation AD and other only toxic immune response
• Brain atrophy neurodegenerative oligomers, not against toxic
diseases monomer or plaque oligomers
Aβ accumulation is slow and protracted, taking 20 to 30 years before cognitive symptoms
This lengthy pre-symptomatic phase of AD provides a substantial opportunity to detect neuropathology,
prevent further brain abnormalities and treat patients before symptoms appear
13Billions of neurons are killed leading to the
Alzheimer’s (AD) brain
Brain with Mild Brain with AD1
Healthy Brain
Cognitive Impairment
15 years pre-symptomatic 5 years MCI 10 years Alzheimer’s
Toxic oligomers of amyloid cause tau to become toxic, increase neuroinflammation, neurons and
synapses die
Neurofilament light (NfL) increases as neurons die at faster rate, P-tau181 increases as
amyloid oligomers increase toxic tau oligomers
1 Reviewed in Bloom 2014, JAMA Neurol
14Alzheimer’s disease: soluble toxic Aβ oligomers – not plaque or
monomers – are the most neuropathogenic Aβ species
• Synapse abnormalities and memory impairment correlate poorly In vivo impairment of recognition memory
with plaque burden in human and mouse AD1,2
by Ab oligomers, not monomers and not fibrils10
• Aβ monomers and Aβ insoluble fibrils (plaque) have little or no Monomers Oligomers Fibrils
demonstrable toxicity in vitro or in vivo3-5
• Soluble Aβ oligomers show the highest degree of neurotoxicity6
• Toxicity in primary neuron cultures and brain slices3,5,7-9
• Induction of cognitive impairment in rodents3,4,10
Synaptotoxicity of human Ab oligomers
on hippocampal neurons in vitro7
5min 6h 24h 24h control
Normal Monomers Oligomers Fibrils
Ab species injected
1Jacobsen et al, 22006, PNAS; 2Brier et al, 2016, Science Trans Med; 3Shankar et al, 2008, Nature Med; 4Cleary et al, 2005, Nature
Neuroscience; 5Hong et al, 2016, Science; 6Benilova et al, 2012, Nature Neuroscience - Review; 7Lacor et al, 2007, J Neuroscience; 8Jin et 15
al, 2011, PNAS; 9Lauren et al, 2009, Nature; 10Balducci et al, 2010, PNASPMN310: an anti-Aβ-oligomer antibody with strong
potential to demonstrate best-in-class characteristics
Biogen’s aducanumab EMERGE study validates the amyloid hypothesis
Aducanumab and BAN2401 are only partially selective for amyloid
oligomers
• Aducanumab (phase 3) and BAN2401 (phase 2) showed modest but meaningful
efficacy in reducing cognitive worsening
• Both significantly bind amyloid plaque → ARIA-E (patchy brain swelling)
• Neither bind monomer (the physiologic amyloid species)
PMN310 is a next-generation, best-in-class anti-amyloid therapy
• Highly selective for only toxic oligomers
Aβ amino acids 13-16 (HHQK)
• Dose will not be limited by off-target binding or side effects
A unique, Aβ oligomer specific
• Does not bind monomer epitope targeted by PMN310
• Does not bind plaque → likely no ARIA-E
• All dosed PMN310 will focus on neutralizing toxic oligomers → potential greater
clinical efficacy
16There are three forms of amyloid, choosing the correct target is critical….
Toxic oligomers –
Toxic oligomers
thousands
–
of scientific
Plaque
Plaque – usually
– usually present,
Monomer – Important Toxic oligomers –
Forms of Monomer – health
Important thousands of scientific butpresent,
no –significant
Plaque role
no in
butpresent,
usually
for brain
Monomer – Important studies showing
thousands of scientific
Amyloid for brain health studies showing but diseaserole
significant
no significant in in
role
for brain health neurotoxicity
studies showing
neurotoxicity disease
disease
neurotoxicity
10 programs/25 phase
2 and 3 clinical trials
targeting monomer
Amyloid All negative
Binding 4 programs/13 phase 2 and 3 clinical trials non-selectively targeting all forms of amyloid, wasted
profile of too much ammunition on abundant monomer to be effective
clinical All negative
programs Two drugs: Biogen’s aducanumab and EISAI’s BAN2401 partially selective
FOUR OUT OF FOUR POSITIVE*(Two Phase 2 trials, one
Phase 3 program*)
!!! DOSE-LIMITING TOXICITY side effect ARIA-E** due to plaque binding !!!
* Using Biogen’s presentation of patients consenting to V4 amendment, receiving 10mg dosing
17
** ARIA-E (Amyloid Related Imaging Abnormality- Edema) also known as brain swellingFour positive trials…partially selective antibodies…higher dose over long duration
leads to better outcomes, but all limited by patchy brain swelling (ARIA-E)
Biogen Ph1b “PRIME” Eisai BAN2401 Phase 2 Biogen pivotal EMERGE Biogen pivotal ENGAGE
December 2014 July 2018 Dec 2019* Dec 2019**
* Final Intent-to-treat data set ** Post-protocol version 4 data set 18The three largest products in industry history were not first in class, but
“best in class” – the inventors identified improvements to existing drugs
ProMIS following the “best in
class” playbook with PMN310
Peak
Sales • Improved selectivity for toxic
$BB’s oligomers
$25BB • No binding to plaque = Lower
risk of ARIA-E = Better safety
$16BB • Ability to safely dose higher
$12BB • No “waste of ammunition” on
non-toxic amyloid -> Greater
efficacy
Lipitor Humira Sovaldi/Harvoni
Cholesterol RA, Crohn’s Hepatitis C
1996 2003 2014
19Binding the right form of toxic oligomer is critical……
Bapineuzumab (Pfizer) Solanezumab (Eli Lilly) Aducanumab (Biogen) PMN310
• Phase 2 failure • Phase 2 failure • Phase 2 & 3 success • Selective binding to
• Phase 3 failure • Phase 3 failure • ARIA-E side effect oligomers
• ARIA-E side effect -> Expected improvement in
efficacy & safety
MONOMERS
- binding wastes
therapeutic ammunition
FIBRILS (Plaque)
- binding wastes
therapeutic ammunition
- contributes to ARIA-E
side effect
OLIGOMERS*
- the right target
* Synthetic oligomers 20ARIA-E associated with aducanumab, BAN2401 & bapineuzumab; PMN310 lack of binding
to Aβ plaque strongly suggests a potential safety advantage
Aducanumab PMN310
Plaque
No binding to plaque
binding
or vascular deposits
Most likely no ARIA-E*
Vascular
deposit
binding
* ARIA-E (Amyloid Related Imaging Abnormality- Edema) also known as brain swelling 21PMN310 shows superior binding to toxic oligomers from human AD brains vs other
antibodies directed against amyloid-beta
50
• Binding of antibodies to the toxic oligomer-
Binding Response (RU)
40
enriched LMW fraction of soluble human AD
brain extract was evaluated by surface
30 plasmon resonance (SPR)
20 • Results representative of over 10 SPR runs
with extracts from 11 different AD brains
10 • huIgG1 = Background control
0
ab
ab
1
0
G
31
m
m
Ig
N
nu
zu
hu
PM
eu
ca
ed
in
du
ap
iz
A
an
B
um
H
Source for comparative reagents: Creative Biolabs 22Administration of PMN310 to mice: prevents loss of short-term memory
formation caused by toxic oligomers, by saving mouse neurons
THE EXPERIMENT 0.6 THE RESULTS
Discrimination Index
• Mice are tested for discriminating objects after * *
0.4
brain injection of:
• Buffer (vehicle) - normal response 0.2
• Toxic Aβ oligomer 0.0 #
• PMN310 and buffer (vehicle) PMN310 PMN310
-0.2
Vehicle AβO + vehicle + AβO
• PMN310 and Aβ Oligomer N=12 per arm, *different from AβO (p < 0.05), #different from vehicle (pPMN310: potential for value-creating clinical data in the near term
- likely positive market developments could amplify PMN value
2020 2021 2022
Aducanumab Aducanumab Aducanumab Launch and Market Development BAN2401
Filing Approval - Reimbursement, Med Ed: ARIA-E screening Ph 3 data
ProMIS Sporadic AD Phase 1: 3 month Pbo control,
Final IND enabling work 9 month extension, MAD design
AD in Down Syndrome - prevention, Potential Approval Path:
treatment, or both: Biomarker and AD in Down Syndrome
clinical endpoint readout
• Recent advances in blood-based biomarkers may allow ProMIS to detect an objective treatment
signal as early as Phase 1, potentially providing rapid & cost-effective proof-of-concept
24ProMIS plans to use biomarkers in its first clinical study, which could show a
disease modifying treatment effect at a cost of $5MM-$10MM
Placebo/ Large
Placebo dataset as an historical control natural history
100* dataset
Potential biomarkers:
3 mg/kg NfL – Neuronal Loss
Blood 10 mg/kg P-tau181 - tau toxicity
NfL Potential for meaningful data 20 mg/kg Others
in 6-12 months from trial start…
40 mg/kg
80 mg/kg
0 6 12 Months
* 100 = patient baseline value Dose escalation design: 3-month placebo-control, then 9-month open-label extension
25Alzheimer’s/Dementia screening, diagnosis, and disease monitoring
Historical: AD Recent advance: …Plus proprietary
Future Vision A/T/N
diagnosis at autopsy A/T/N assays
Amyloid PET TDP43 , Alpha Synuclein
P-tau181 - Differential diagnosis
Blood based
Tau PET
Other assays – overall
NfL algorithm
Cortical MRI Blood based
~$100
$10,000 - $15,000
26ProMIS/BCNI Joint Venture to build a diagnostic revenue base
• Significant progress over past several yrs. to advance a more precise diagnosis of AD
• Introduction of A/T/N (amyloid/tau/neurodegeneration) criteria 2 years ago offered an unbiased approach for
objective biological diagnosis of AD
• However, the A/T/N diagnostic approach, until recently, required either costly PET and MRI scan assessments or
invasive lumbar puncture to measure specific biomarkers in cerebrospinal fluid (CSF)
• Blood levels of NfL (neurofilament light chain) and P-tau181 (phosphorylated tau181)
• Provide equally precise A/T/N characterization as imaging or CSF measurements, and can thus offer convenient, cost-
effective and objective detection and monitoring of the AD process
• JV/collaboration to first offer existing blood-based assays for NfL and P-tau181
• Further assays to be added potentially incorporating ProMIS’ proprietary peptide antigens & tests for additional
neurodegenerative diseases
• ProMIS’ ultimate mission with its partner, BCNI, is to build a portfolio of assays that enables early detection and
monitoring of disease progression before symptoms arise
• Discussions for screening projects have started – goal revenue in 2021, possibly Q4 2020
27ProMIS therapeutic vaccine for Alzheimer’s disease
• Large patient population with symptomatic AD in need of effective treatment (n≥5M, USA) –> Therapeutic vaccination
• Ever greater number of individuals in the pre-symptomatic phase of the disease (potentially 40% of the population over 65, ~50M) –
> Prophylactic preventative vaccine
• Vaccine approach will benefit from recent progress in the development of blood-based biomarkers of neurodegeneration to diagnose
AD and identify individuals at risk of developing disease
• ProMIS discovery platform being applied to devise a safe and effective vaccine to induce a specific immune response
against toxic Ab oligomers
• Identified a set of 6 conformational peptide epitopes selectively exposed on toxic Ab oligomers
• All 6 peptide epitopes shown to be capable of inducing selective and protective antibodies against toxic Ab oligomers
• Successful proof of concept vaccination study conducted with one of the peptides (cSNK) in a mouse model of AD (APP/PS1
mice): Neuronal protection and improvement in cognitive deficits2
• Concept: multivalent vaccine with some or all 6 Ab peptides. Tau peptides recently identified could also be included.
• Immediate aims: Construct and test multivalent Ab vaccine for ability to induce a protective antibody response
1Marciani DJ, 2019, AAAS Research, https://doi.org/10.34133/2019/5341375; 2Silverman, JM et al, 2018, ACS Chem Neurosci
28Benefit of vaccination with ProMIS Ab oligomer (AbO) epitope
Mice vaccinated with conformational Ab oligomer Biological support for multivalent vaccine approach:
epitope (cSNK) coupled to KLH Greater binding with mixture of sera from mice
immunized with different AbO epitopes vs immune
Robust, sustained antibody Improvement in behavioral serum against individual peptides
response (SPR) deficits of APP/PS1 mice
HFIP Ab Untreated Ab
monomers
AbM(HFIP) monomers
AbM(untreated) AbO
AbO(SynAging)
80
SPR
60
Binding Response (RU)
40
Protection against synaptic damage
20
0
-100
5)
5)
5)
5)
5)
S
05
M
Silverman et al.
1:
1:
1:
1:
1:
,3
N
S(
S(
S(
S(
S(
04
(normal
M
M
M
M
M
3
2018. ACS Chem
N
N
N
N
N
3,
1-
2-
3-
4-
5-
30
mouse serum)
30
30
30
30
30
Neurosci 9: 1591-
,
02
N
N
N
N
N
3
PM
PM
PM
PM
PM
1,
1606 29
30
N
PMProMIS: current portfolio of antibodies selectively targeting
toxic mis-folded proteins
Predict Produce Prioritize Lead program early POC
Scientific Literature:
mis-folded protein role Assess functional IND enabling
Predict
Immunize and screen benefit in vitro and in development
in disease conformational
antibody candidates vivo; assess binding Biomarker readouts
pathogenesis; epitopes on target
for selectivity strength to enriched of pharmacologic
role of other forms molecular species
patient biomaterial effect in Ph1
(molecular species)
PMN310, ready for final
Amyloid beta
IND enabling work
Several leads, active
Alpha Synuclein partnering discussions
Several leads, active
TDP43
partnering discussions
tau Early leads, immunization ongoing , active partnering discussions
Many ongoing discovery: RACK1, DISC1, FUS, SOD1, Amylin, PrP,
other
30ProMIS Summary Investment Thesis
• Unique technology platform – rapid, cost-effective, differentiated
• Rapid response to COVID-19; goal to create differentiated immunity serology assay, potential near term revenue if
successful
• Strategic portfolio in Alzheimer’s based on unique platform – Detect – Treat – Prevent
• PMN310 scientifically superior to likely “first in class” therapy Biogen’s aducanumab, PMN310 selective for toxic
oligomers, stronger binding
• Biogen filed for regulatory approval, potential launch mid 2021, will be strong catalysts for the field, especially
improved amyloid targeted therapies like PMN310
• ProMIS broad portfolio, programs targeting mis-folded versions of TDP43, alpha synuclein, tau, ongoing partnering
discussions (timing affected by industry priority shift to COVID, lab closures, etc.)
• Aducanumab launch will also likely lead to dramatic growth in demand for screening and diagnosis of dementia
• ProMIS JV with BCNI will enable capitalizing on that growing demand with both established and proprietary assays
• ProMIS technology enables potential Alzheimer’s vaccine – building on early POC
31Experienced leadership team
Name Title Years of Experience Prior Experience
§ Former SVP at Genzyme, with senior roles integrating commercialization, drug
development, and deal making
Gene Williams Executive Chairman 25+ § Recently the CEO of Dart Therapeutics, an Orphan Disease drug development
company
§ Founder and director of Adheris, which became the largest company in the
patient adherence/compliance area
§ Held positions as SVP of Strategic Product Development at SmithKline
Beecham (now GSK)
Elliot Goldstein CEO 25+ § Chief Operating Officer and Chief Medical Officer of Maxygen
§ Chief Operating Officer at DART Therapeutics
§ Holds the Canada Research Chair in Neurodegeneration and Protein
Misfolding Diseases,
Neil Cashman Chief Science Officer 25+ § Serves as the Director of the University of British Columbia ALS
Centre,
§ Awarded the Jonas Salk Prize for biomedical research in 2000
§ Professor at UBC in the Department of Physics and Astronomy since 2001
§ Appointed as the Canada Research Chair in Theoretical Molecular Biophysics
Steven Plotkin Chief Physics Officer 20 § Associate member of the Genome Sciences and Technology Program, the
Bioinformatics Program, and the Institute for Applied Mathematics at the
University of British Columbia
§ Founding Managing Director of Danforth Advisors
§ Served as the Chief financial officer of Homology, Inc, GenePeeks,
Dan Geffken CFO 25+ Inc., Transkaryotic Therapies, Inc., Cidara, Inc., Apellis, Inc. and
Stealth BioTherapeutics, Inc.
§ Former VP of Research at Genzyme
Chief Development 25+
§ Associate Immunopathologist at SmithKline Beecham where she
Johanne Kaplan Officer
established an Immunotoxicology program
§ Her work has resulted in over 60 scientific publications and multiple patents
§ Former VP, Global Clinical Leader for Parkinson’s disease, and Clinical Head
of the Neuroscience Research Unit for Pfizer, Inc
James Kupiec Chief Medical Officer 25+ § Clinical focus on development of therapies for neurodegenerative disorders
§ Held positions at Sanofi-Synthelabo and Ciba-Geigy Pharmaceuticals
30Independent board of directors
Name Years of Experience Prior Experience
§ President and CEO of Sunovion CNS Development
25+ Canada ULC
Anthony Giovinazzo § President, CEO and a Director of Cynapsus Therapeutics
from 2009 to 2016 and one of the three original inventors
and patent holders of the company’s Parkinson’s focused
technology
§ Chief Scientific Officer & Executive VP for Research at
25+ ImmunoGen
Richard Gregory § Held a variety of roles at Genzyme and Sanofi-Genzyme,
including Vice President for Gene Therapy, Head of
Corporate Research and Head of R&D
§ Co-founded the management consulting firm, Oliver
40+ Wyman & Co
Bill Wyman § Former President of the Management Consulting Group
called Booz Allen and Hamilton
15+ § Founding director and partner at FiveT Capital Holding AG
§ A board member of Insilico Biotechnology AG
Johannes Roth
Pat Kirwin § Senior partner at Kirwin LLP
30+ § Advises and represents businesses in a range of industries and
sizes from local to multinational
33
31Scientific Advisory Board
Name Years of Experience Prior Experience Affiliations
Medical Director & Principal Investigator of Toronto Memory Program
Sharon Cohen, MD 20+ FRCPC in neurology from Royal College of Physicians of Canada and a fellowship in
Behavioural Neurology from the University of Toronto
Director of the Center for Translational Research in Neurodegenerative Disease at the
Todd Golde, MD, PhD 20+ University of Florida
Dean for Neurosciences Initiatives, Distinguished Professor of Neurosciences, and
Bill Mobley, MD, PhD 25+ Florence Riford Chair for Alzheimer Disease at the University of California, San Diego
Scientific Director, Alzheimer Prevention Program at Barcelonaβeta Brain Research
José Molinuevo, MD, PhD 20+ Center, Barcelona Spain
Associate Professor, Pompeu Fabra University, Barcelona, Spain
Previous Henry P & Georgette Goldschmidt Professor & Chairman, Department of
C. Warren Olanow, MD 25+ Neurology at Mount Sinai School of Medicine, presently Professor Emeritus Department
of Neurology & Department of Neuroscience, CEO of CLINTREX
Professor Institute of Psychiatry, Psychology and Neuroscience at King’s College
Andre Strydom, MD, PhD 25+ London
Honorary Consultant psychiatrist, South London and the Maudsley NHS Foundation
Trust
Professor of Neurology at Harvard University, Vice Chair of Neurology, Director of
Rudy Tanzi, PhD 20+ Genetics & Aging Research Unit, Co-Director McCance Center for Brain Health at Mass
General Hospital
Associate Professor of Neurology and Research Professor at Emory University Yerkes
Lary Walker, PhD 20+ National Primate Research Center
Hans Frykman, MD, PhD Clinical assistant professor of medicine at the University of British Columbia
20+ CEO and Medical Director of BC Neuroimmunology Lab (BCNI)
32Thank You
Please feel free to contact us with any additional questions.
Eugene Williams, Executive Chairman Elliot Goldstein, MD, CEO
eugene.williams@promisneurosciences.com elliot.goldstein@promisneurosciences.com
+1 (617) 460-0978 +1 (415) 341-5783
Website: www.promisneurosciences.com
Twitter: https://twitter.com/ProMISinc
LinkedIn:
https://www.linkedin.com/company/promis-
neurosciences
35You can also read
